CMS acquired the product Traumakine? of Faron

Company News

CMS acquired the assets (the “Product Assets”) related to the product Traumakine® in China, Hong Kong, Macau and Taiwan (the “Territory”) of Faron Pharmaceuticals. This transaction shows that the group has extended the bring-in products assets from marketed types to the overseas products which in the late research and development stage. Traumakine® is a Recombinant Human Interferon beta-1a intravenous lyophilized preparation for the treatment of acute respiratory distress syndrome (ARDS).

The terms and conditions of this transfer, including the consideration for the transfer of the Product Assets, will be further negotiated and agreed at a later stage prior to the launch of the Product in the Territory.